The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model

Cancer Gene Therapy

Volumn 21, Issue 2, 2014, Pages 68-73

  Puig Saus, C ^a   Laborda, E ^a,b   Rodriguez Garcia A ^a   Cascallo M ^a   Moreno, R ^a   Alemany, R ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

gemcitabine; intratumoral spread; oncolytic adenovirus; oncolytic potency; Syrian hamster; viral release

Indexed keywords

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CRICETINAE; DEOXYCYTIDINE; DNA PRIMERS; FLUORESCENCE; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MESOCRICETUS; MICE; MUTATION, MISSENSE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PROTEIN SORTING SIGNALS; STATISTICS, NONPARAMETRIC; VIRUS RELEASE;

EID: 84894237841     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.85     Document Type: Article

References (40)

1. Pesonen S, Kangasniemi L, Hemminki A. Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 2011; 8: 12-28.
2. Alemany R. Design of improved oncolytic adenoviruses. Adv Cancer Res 2012; 115: 93-114.
3. Ganesh S, Gonzalez Edick M, Idamakanti N, Abramova M, Vanroey M, Robinson M et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res 2007; 67: 4399-4407.
4. Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 2010; 18: 1275-1283.
5. Gros A, Guedan S. Adenovirus release from the infected cell as a key factor for adenovirus oncolysis. Open Gene Ther J 2010; 3: 24-30.
6. Puig-Saus C, Gros A, Alemany R, Cascallo M. Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers. Mol Ther 2012; 20: 54-62.
7. Yan W, Kitzes G, Dormishian F, Hawkins L, Sampson-Johannes A, Watanabe J et al. Developing novel oncolytic adenoviruses through bioselection. J Virol 2003; 77: 2640-2650.
8. Subramanian T, Vijayalingam S, Chinnadurai G. Genetic identification of adenovirus type 5 genes that influence viral spread. J Virol 2006; 80: 2000-2012.
9. Rojas JJ, Guedan S, Searle PF, Martinez-Quintanilla J, Gil-Hoyos R, Alcayaga-Miranda F et al. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Mol Ther 2010; 18: 1960-1971.
10. Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WS. Tumorspecific replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 2000; 74: 6147-6155.
11. Gros A, Martinez-Quintanilla J, Puig C, Guedan S, Mollevi DG, Alemany R et al. Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. Cancer Res 2008; 68: 8928-8937.
12. Gros A, Puig C, Guedan S, Rojas JJ, Alemany R, Cascallo M. Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses. Mol Ther 2010; 18: 903-911.
13. Alemany R, Cascallo M. Oncolytic viruses from the perspective of the immune system. Future Microbiol 2009; 4: 527-536.
14. Khoobyarian N, Barone F, Sabet T, El-Domeiri AA, Das Gupta TK. Inhibition of melanoma growth in hamsters by type-2 adenovirus. J Surg Oncol 1975; 7: 421-425.
15. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270-1276.
16. Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WS. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther 2008; 16: 1665-1673.
17. Cherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Muller H, Lemoine NR et al. The oncolytic adenovirus AdDeltaDelta enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models. Gene Ther 2011; 18: 1157-1165.
18. Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine NR et al. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res 2009; 15: 1730-1740.
19. Onimaru M, Ohuchida K, Nagai E, Mizumoto K, Egami T, Cui L et al. Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer. Cancer Lett 2010; 294: 178-186.
20. Nelson AR, Davydova J, Curiel DT, Yamamoto M. Combination of conditionally replicative adenovirus and standard chemotherapies shows synergistic antitumor effect in pancreatic cancer. Cancer Sci 2009; 100: 2181-2187.
21. Bortolanza S, Bunuales M, Alzuguren P, Lamas O, Aldabe R, Prieto J et al. Deletion of the E3-6.7 K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters. Cancer Gene Ther 2009; 16: 703-712.
22. Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555-561.
23. Bhattacharyya M, Francis J, Eddouadi A, Lemoine NR, Hallden G. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. Cancer Gene Ther 2011; 18: 734-743.
24. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA et al. Stromal biology and therapy in pancreatic cancer. Gut 2010; 60: 861-868.
25. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30: 658-670.
26. Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 2011; 25: 2559-2572.
27. Liu WM, Fowler DW, Smith P, Dalgleish AG. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses. Br J Cancer 2010; 102: 115-123.
28. Plate JM, Plate AE, Shott S, Bograd S, Harris JE. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 2005; 54: 915-925.
29. Rettig L, Seidenberg S, Parvanova I, Samaras P, Curioni A, Knuth A et al. Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int J Cancer 2011; 129: 832-838.
30. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009; 9: 900-909.
31. Ma Y, Kepp O, Ghiringhelli F, Apetoh L, Aymeric L, Locher C et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol 2010; 22: 113-124.
32. Locher C, Conforti R, Aymeric L, Ma Y, Yamazaki T, Rusakiewicz S et al. Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci 2010; 1209: 99-108.
33. Schierer S, Hesse A, Knippertz I, Kaempgen E, Baur AS, Schuler G et al. Human dendritic cells efficiently phagocytose adenoviral oncolysate but require additional stimulation to mature. Int J Cancer 2012; 130: 1682-1694.
34. Chen M, Barnfield C, Naslund TI, Fleeton MN, Liljestrom P. MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells. J Virol 2005; 79: 2964-2972.
35. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005; 433: 887-892.
36. Boozari B, Mundt B, Woller N, Struver N, Gurlevik E, Schache P et al. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma. Gut 2010; 59: 1416-1426.
37. Dias JD, Hemminki O, Diaconu I, Hirvinen M, Bonetti A, Guse K et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther 2012; 19: 988-998.
38. Stanton RJ, McSharry BP, Armstrong M, Tomasec P, Wilkinson GW. Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. Biotechniques 2008; 45: 659-662.
39. Laquente B, Lacasa C, Ginesta MM, Casanovas O, Figueras A, Galan M et al. Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol Cancer Ther 2008; 7: 638-647.
40. Gujar SA, Michalak TI. Flow cytometric quantification of T cell proliferation and division kinetics in woodchuck model of hepatitis B. Immunol Invest 2005; 34: 215-236.